Evaluating Innovative Malaria Diagnostics in Senegal
To support the development and introduction of more sensitive rapid diagnostic tests (RDTs) for malaria, PATH and the Institut Pasteur de Dakar partnered to evaluate the performance of three novel LDH-based RDTs developed by Rapigen (Republic of Korea). This study evaluated the clinical performance and usability of three of Rapigen’s BIOCREDIT RDTs among a febrile population in Kédougou, Senegal, comparing them to current tests (the standard HRP2-based RDT and microscopy) and against PCR and quantitative antigen reference assays. The following brief summarizes key results from this evaluation.
Publication date: July 2025